Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Dale DC, Firkin F, Bolyard AA, Kelley M, Makaryan V, Gorelick KJ, Ebrahim T, Garg V, Tang W, Jiang H, Skerlj R, Beaussant Cohen S.
Dale DC, et al. Among authors: ebrahim t.
Blood. 2020 Dec 24;136(26):2994-3003. doi: 10.1182/blood.2020007197.
Blood. 2020.
PMID: 32870250
Free PMC article.
Clinical Trial.